TLR4 Human shRNA Lentiviral Particle (Locus ID 7099)

CAT#: TL320555V

TLR4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL320555A virus into HEK293 cells. TL320555A virus was prepared using lenti-shRNA TL320555A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL320555B virus into HEK293 cells. TL320555B virus was prepared using lenti-shRNA TL320555B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL320555C virus into HEK293 cells. TL320555C virus was prepared using lenti-shRNA TL320555C and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL320555D virus into HEK293 cells. TL320555D virus was prepared using lenti-shRNA TL320555D and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 7099
• Synonyms: ARMD10; CD284; TLR-4; TOLL
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_003266, NM_138554, NM_138556, NM_138557, NR_024168, NR_024169, BC025294, BC117422, BC143841
• Summary: 'The protein encoded by this gene is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. In silico studies have found a particularly strong binding of surface TLR4 with the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease-2019 (COVID-19). This receptor has also been implicated in signal transduction events induced by lipopolysaccharide (LPS) found in most gram-negative bacteria. Mutations in this gene have been associated with differences in LPS responsiveness, and with susceptibility to age-related macular degeneration. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2020]'
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).